142 related articles for article (PubMed ID: 32287444)
1. A highly facile approach to the synthesis of novel 2-(3-benzyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-N-phenylacetamides.
Novikov MS; Babkov DA; Paramonova MP; Chizhov AO; Khandazhinskaya AL; Seley-Radtke KL
Tetrahedron Lett; 2013 Feb; 54(6):576-578. PubMed ID: 32287444
[TBL] [Abstract][Full Text] [Related]
2. Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses.
Kertesz DJ; Brotherton-Pleiss C; Yang M; Wang Z; Lin X; Qiu Z; Hirschfeld DR; Gleason S; Mirzadegan T; Dunten PW; Harris SF; Villaseñor AG; Hang JQ; Heilek GM; Klumpp K
Bioorg Med Chem Lett; 2010 Jul; 20(14):4215-8. PubMed ID: 20538456
[TBL] [Abstract][Full Text] [Related]
3. Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.
Varghese V; Shahriar R; Rhee SY; Liu T; Simen BB; Egholm M; Hanczaruk B; Blake LA; Gharizadeh B; Babrzadeh F; Bachmann MH; Fessel WJ; Shafer RW
J Acquir Immune Defic Syndr; 2009 Nov; 52(3):309-15. PubMed ID: 19734799
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and anti-HIV-1 activity of 1-substiuted 6-(3-cyanobenzoyl) and [(3-cyanophenyl)fluoromethyl]-5-ethyl-uracils.
Loksha YM; Pedersen EB; Loddo R; La Colla P
Arch Pharm (Weinheim); 2009 Sep; 342(9):501-6. PubMed ID: 19637180
[TBL] [Abstract][Full Text] [Related]
5. Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide.
Buckheit RW; White EL; Fliakas-Boltz V; Russell J; Stup TL; Kinjerski TL; Osterling MC; Weigand A; Bader JP
Antimicrob Agents Chemother; 1999 Aug; 43(8):1827-34. PubMed ID: 10428899
[TBL] [Abstract][Full Text] [Related]
6. Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
Lai MT; Munshi V; Touch S; Tynebor RM; Tucker TJ; McKenna PM; Williams TM; DiStefano DJ; Hazuda DJ; Miller MD
Antimicrob Agents Chemother; 2009 Jun; 53(6):2424-31. PubMed ID: 19289522
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
[TBL] [Abstract][Full Text] [Related]
8. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
Azijn H; Tirry I; Vingerhoets J; de Béthune MP; Kraus G; Boven K; Jochmans D; Van Craenenbroeck E; Picchio G; Rimsky LT
Antimicrob Agents Chemother; 2010 Feb; 54(2):718-27. PubMed ID: 19933797
[TBL] [Abstract][Full Text] [Related]
9. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
Hu Z; Kuritzkes DR
J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
[TBL] [Abstract][Full Text] [Related]
10. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
Santoro MM; Sabin C; Forbici F; Bansi L; Dunn D; Fearnhill E; Boumis E; Nicastri E; Antinori A; Palamara G; Callegaro A; Francisci D; Zoncada A; Maggiolo F; Zazzi M; Perno CF; Ceccherini-Silberstein F; Mussini C
HIV Med; 2013 Oct; 14(9):571-7. PubMed ID: 23668660
[TBL] [Abstract][Full Text] [Related]
11. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
Schiller DS; Youssef-Bessler M
Clin Ther; 2009 Apr; 31(4):692-704. PubMed ID: 19446143
[TBL] [Abstract][Full Text] [Related]
12. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.
Andries K; Azijn H; Thielemans T; Ludovici D; Kukla M; Heeres J; Janssen P; De Corte B; Vingerhoets J; Pauwels R; de Béthune MP
Antimicrob Agents Chemother; 2004 Dec; 48(12):4680-6. PubMed ID: 15561844
[TBL] [Abstract][Full Text] [Related]
13. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
[TBL] [Abstract][Full Text] [Related]
14. Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.
Nicot F; Saliou A; Raymond S; Sauné K; Dubois M; Massip P; Marchou B; Delobel P; Izopet J
J Clin Virol; 2012 Oct; 55(2):107-13. PubMed ID: 22818969
[TBL] [Abstract][Full Text] [Related]
15. A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors.
Motakis D; Parniak MA
Antimicrob Agents Chemother; 2002 Jun; 46(6):1851-6. PubMed ID: 12019100
[TBL] [Abstract][Full Text] [Related]
16. Molecular Hybridization-Inspired Optimization of Diarylbenzopyrimidines as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors with Improved Activity against K103N and E138K Mutants and Pharmacokinetic Profiles.
Han S; Sang Y; Wu Y; Tao Y; Pannecouque C; De Clercq E; Zhuang C; Chen FE
ACS Infect Dis; 2020 May; 6(5):787-801. PubMed ID: 31599568
[TBL] [Abstract][Full Text] [Related]
17. Dihydro-alkylthio-benzyl-oxopyrimidines as inhibitors of reverse transcriptase: synthesis and rationalization of the biological data on both wild-type enzyme and relevant clinical mutants.
Mugnaini C; Alongi M; Togninelli A; Gevariya H; Brizzi A; Manetti F; Bernardini C; Angeli L; Tafi A; Bellucci L; Corelli F; Massa S; Maga G; Samuele A; Facchini M; Clotet-Codina I; Armand-Ugón M; Esté JA; Botta M
J Med Chem; 2007 Dec; 50(26):6580-95. PubMed ID: 18052319
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.
Marcelin AG; Flandre P; Descamps D; Morand-Joubert L; Charpentier C; Izopet J; Trabaud MA; Saoudin H; Delaugerre C; Tamalet C; Cottalorda J; Bouvier-Alias M; Bettinger D; Dos Santos G; Ruffault A; Alloui C; Henquell C; Rogez S; Barin F; Signori-Schmuck A; Vallet S; Masquelier B; Calvez V;
Antimicrob Agents Chemother; 2010 Jan; 54(1):72-7. PubMed ID: 19901096
[TBL] [Abstract][Full Text] [Related]
19. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
Gupta S; Fransen S; Paxinos EE; Stawiski E; Huang W; Petropoulos CJ
Antimicrob Agents Chemother; 2010 May; 54(5):1973-80. PubMed ID: 20194692
[TBL] [Abstract][Full Text] [Related]
20. Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors.
Ceccherini-Silberstein F; Svicher V; Sing T; Artese A; Santoro MM; Forbici F; Bertoli A; Alcaro S; Palamara G; d'Arminio Monforte A; Balzarini J; Antinori A; Lengauer T; Perno CF
J Virol; 2007 Oct; 81(20):11507-19. PubMed ID: 17686836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
